Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7130506 | 0.84 | TP53 (0.43) | EPHX2CHRNA7HTR3ATP53SMN1; SMN2 | |
| SCHEMBL7130674 | 0.80 | NOS1 (0.38) | EPHX2 | |
| SCHEMBL7128085 | 0.79 | EPHX2 (0.53) | EPHX2TP53SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL7121104 | 0.74 | HTR3A (0.46) | EPHX2CHRNA7HTR3A | |
| SCHEMBL7982160 | 0.73 | FADS1 (0.54) | EPHX2CHRNA7HTR3ATP53SMN1; SMN2 | |
| SCHEMBL8114894 | 0.68 | EPHX2 (0.59) | EPHX2CHRNA7HTR3A | |
| SCHEMBL7082812 | 0.66 | MEN1 (0.55) | SMN1; SMN2ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL14260120 | 0.66 | KMT2A (0.50) | SMN1; SMN2ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL2442075 | 0.66 | SMN1; SMN2 (0.45) | EPHX2CHRNA7HTR3ATP53SMN1; SMN2 | |
| SCHEMBL30667408 | 0.65 | EPHX2 (0.64) | EPHX2CHRNA7HTR3ATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | EPHX2 354/4885CHRNA7 658/4885HTR3A 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.